EDIT-301
EM-SCD-301-001
Phase 2 gene_therapy active
Quick answer
EDIT-301 for Sickle Cell Disease is a Phase 2 program (gene_therapy) at Editas Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Editas Medicine
- Indication
- Sickle Cell Disease
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- active